NASDAQ:AVDL - Avadel Pharmaceuticals Stock Price, News, & Analysis

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Avadel Pharmaceuticals declared that its Board of Directors has initiated a share buyback plan on Wednesday, March 28th 2018, which authorizes the company to repurchase $7,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 2.7% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's management believes its stock is undervalued.

Avadel Pharmaceuticals PLC (NASDAQ:AVDL) posted its quarterly earnings results on Tuesday, August, 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.37) by $0.28. The company had revenue of $29.23 million for the quarter, compared to analyst estimates of $25.02 million. Avadel Pharmaceuticals had a negative net margin of 2.39% and a negative return on equity of 46.58%. View Avadel Pharmaceuticals' Earnings History.

Avadel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Avadel Pharmaceuticals.

5 analysts have issued twelve-month price objectives for Avadel Pharmaceuticals' shares. Their forecasts range from $14.00 to $30.00. On average, they expect Avadel Pharmaceuticals' share price to reach $22.6667 in the next year. This suggests a possible upside of 382.3% from the stock's current price. View Analyst Price Targets for Avadel Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avadel Pharmaceuticals.

Some companies that are related to Avadel Pharmaceuticals include Kura Oncology (KURA), Aptinyx (APTX), CymaBay Therapeutics (CBAY), Crinetics Pharmaceuticals (CRNX), Kiniksa Pharmaceuticals (KNSA), Epizyme (EPZM), Geron (GERN), ANI Pharmaceuticals Inc Common Stock (ANIP), Vectura Group (VEGPF), Abeona Therapeutics (ABEO), Urogen Pharma (URGN), Viking Therapeutics (VKTX), Adamas Pharmaceuticals (ADMS), GlycoMimetics (GLYC) and AC Immune (ACIU).

News stories about AVDL stock have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Avadel Pharmaceuticals earned a coverage optimism score of 0.12 on Accern's scale. They also assigned news stories about the company an impact score of 45.69 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View Recent Headlines for Avadel Pharmaceuticals.

Avadel Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Brandes Investment Partners LP (13.53%), Acadian Asset Management LLC (3.62%), Renaissance Technologies LLC (2.86%), BlackRock Inc. (1.33%), Millennium Management LLC (0.90%) and GSA Capital Partners LLP (0.64%). Company insiders that own Avadel Pharmaceuticals stock include Craig R Stapleton, Francis Fildes, Greg J Divis, Guillaume Cerutti, Healthcare Master Fun Broadfin, James E Flynn, Michael S Anderson, Peter J Thornton, Phillandas T Thompson and Sandra L Hatten. View Institutional Ownership Trends for Avadel Pharmaceuticals.

AVDL stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, GSA Capital Partners LLP, Portolan Capital Management LLC, BlackRock Inc., Alps Advisors Inc. and Alps Advisors Inc.. Company insiders that have sold Avadel Pharmaceuticals company stock in the last year include Craig R Stapleton, James E Flynn, Michael S Anderson and Sandra L Hatten. View Insider Buying and Selling for Avadel Pharmaceuticals.

AVDL stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC, Brandes Investment Partners LP, Commonwealth of Pennsylvania Public School Empls Retrmt SYS, Investors Asset Management of Georgia Inc. GA ADV and Quantitative Systematic Strategies LLC. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Craig R Stapleton, Greg J Divis, Michael S Anderson, Peter J Thornton, Phillandas T Thompson and Sandra L Hatten. View Insider Buying and Selling for Avadel Pharmaceuticals.

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AVDL stock can currently be purchased for approximately $4.70.

Avadel Pharmaceuticals has a market capitalization of $181.52 million and generates $172.74 million in revenue each year. The company earns $68.27 million in net income (profit) each year or $0.31 on an earnings per share basis. Avadel Pharmaceuticals employs 180 workers across the globe.

Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 636-449-1830 or via email at investors[email protected]